Mirae Asset Global Investments
APLS

Mirae Asset Global Investments’s Apellis Pharmaceuticals APLS Stock Holding History

Mirae Asset Global Investments’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,668
Closed -$268K – 1675
2026
Q1 		$268K Buy
6,668
+520
+8% +$11.2K ﹤0.01% 1030
2025
Q4 		$154K Buy
6,148
+1,266
+26% +$29.7K ﹤0.01% 1195
2025
Q3 		$110K Buy
4,882
+27
+0.6% +$630 ﹤0.01% 1193
2025
Q2 		$84K Buy
4,855
+655
+16% +$12.1K ﹤0.01% 1171
2025
Q1 		$102K Buy
4,200
+55
+1% +$1.52K ﹤0.01% 1126
2024
Q4 		$135K Sell
4,145
-259
-6% -$7.79K ﹤0.01% 1107
2024
Q3 		$130K Buy
4,404
+781
+22% +$28.9K ﹤0.01% 1152
2024
Q2 		$150K Sell
3,623
-46,676
-93% -$2.11M ﹤0.01% 1089
2024
Q1 		$3.22M Buy
+50,299
New +$3.21M 0.01% 1012
2023
Q2 		– Sell
-50,462
Closed -$3.33M – 2606
2023
Q1 		$3.33M Buy
50,462
+5,283
+12% +$305K 0.01% 983
2022
Q4 		$2.34M Buy
45,179
+2,291
+5% +$122K 0.01% 1076
2022
Q3 		$2.93M Buy
42,888
+14,162
+49% +$838K 0.01% 995
2022
Q2 		$1.3M Buy
+28,726
New +$1.31M ﹤0.01% 1285

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Mirae Asset Global Investments's APLS Position: Q2 2026 in Review

Mirae Asset Global Investments sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 6,668 shares — an estimated $268K sold.

Mirae Asset Global Investments first reported a position in APLS in Q2 2022 and held it in 13 quarters. The position peaked at $3.33M in Q1 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Mirae Asset Global Investments reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Mirae Asset Global Investments sold 6,668 Apellis Pharmaceuticals shares in Q2 2026, an estimated $268K.
  • Mirae Asset Global Investments first reported a position in Apellis Pharmaceuticals in Q2 2022 and held it in 13 quarters.
  • Mirae Asset Global Investments's Apellis Pharmaceuticals position peaked at $3.33M in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.